Related Experiment Video
Updated: Jun 13, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Designing T cells for cancer immunotherapy
Leslie E Huye1, Gianpietro Dotti
1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston 77030, United States. lehuye@txccc.org
Abstract:
Adoptive transfer of T cells can enhance immune-mediated elimination of tumor cells and provides a specific, non-toxic cancer therapy. This approach has been effective in treating some hematologic and solid malignancies. In addition, the ability to genetically modify T cells to enhance their activity and persistence as well as overcome tumor immune evasion mechanisms has the potential to increase the success of these therapies in a wide range of tumors. In this review we discuss methods for gene transfer and specific modifications that have been made to T cells.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

